

# Sungjune Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12005510/publications.pdf>

Version: 2024-02-01

19  
papers

1,367  
citations

759233

12  
h-index

839539

18  
g-index

19  
all docs

19  
docs citations

19  
times ranked

2600  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of epigenomic alterations in HPV16+ head and neck squamous cell carcinomas. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , cebp.EPI-21-0922-A.2021.	2.5	6
2	Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune system. <i>Neoplasia</i> , 2022, 28, 100796.	5.3	15
3	Epigenetic dysregulation of immune-related pathways in cancer: bioinformatics tools and visualization. <i>Experimental and Molecular Medicine</i> , 2021, 53, 761-771.	7.7	8
4	Nivolumab and Stereotactic Radiosurgery for Patients with Breast Cancer Brain Metastases: A Non-Randomized, Open-Label Phase Ib Study. <i>Advances in Radiation Oncology</i> , 2021, 6, 100798.	1.2	5
5	Methylation of immune synapse genes modulates tumor immunogenicity. <i>Journal of Clinical Investigation</i> , 2020, 130, 974-980.	8.2	34
6	Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1012-1021.	0.8	105
7	<i>PTPN11</i> Plays Oncogenic Roles and Is a Therapeutic Target for <i>BRAF</i> Wild-Type Melanomas. <i>Molecular Cancer Research</i> , 2019, 17, 583-593.	3.4	34
8	Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel. <i>Blood</i> , 2018, 132, 4220-4220.	1.4	7
9	Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. <i>Journal of Neuro-Oncology</i> , 2017, 133, 331-338.	2.9	107
10	The future of personalised radiotherapy for head and neck cancer. <i>Lancet Oncology</i> , The, 2017, 18, e266-e273.	10.7	168
11	Novel Opportunities to Use Radiation Therapy with Immune Checkpoint Inhibitors for Melanoma Management. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 515-529.	1.5	16
12	Systematic review of case reports on the abscopal effect. <i>Current Problems in Cancer</i> , 2016, 40, 25-37.	2.0	412
13	The immune mechanisms of abscopal effect in radiation therapy. <i>Current Problems in Cancer</i> , 2016, 40, 10-24.	2.0	131
14	Phase 2 Study of Concurrent Cetuximab Plus Definitive Thoracic Radiation Therapy Followed by Consolidation Docetaxel Plus Cetuximab in Poor Prognosis or Elderly Patients With Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 828-833.	0.8	11
15	Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1009-1021.	4.2	40
16	PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells. <i>Journal of Immunology</i> , 2009, 182, 2816-2826.	0.8	178
17	Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants. <i>Expert Review of Vaccines</i> , 2008, 7, 1519-1532.	4.4	31
18	Impact of bacteria on the phenotype, functions, and therapeutic activities of invariant NKT cells in mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 2301-15.	8.2	59

#	ARTICLE	IF	CITATIONS
19	Role of the programmed death-1 (PD-1) pathway in glycolipid-induced iNKT cell anergy. FASEB Journal, 2008, 22, 397-397.	0.5	0